What will it take to get therapies approved for type 1 diabetes?

Annals of the New York Academy of Sciences

Volumn 1150, Issue , 2008, Pages 25-31

  Fleming, Alexander ^a,b  

^a Kinexum   (United States)

^b NONE   (United States)

Author keywords

C peptide; FDA; Hypoglycemia; Immunomodulatory; Insulin; Regulatory; T1D

Indexed keywords

C PEPTIDE; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; IMMUNOMODULATING AGENT; INSULIN; LISOFYLLINE; MECASERMIN RINFABATE; ROFECOXIB; ROSIGLITAZONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DRUG DOSE REGIMEN; DRUG EFFICACY; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; ONSET AGE; OPTIMAL DRUG DOSE; REMISSION;

EID: 57749200127     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1447.043     Document Type: Conference Paper

References (18)

1. National Institute of Diabetes and Digestive and Kidney Diseases. 2003. National Diabetes Statistics Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2003. U.S. Department of Health and Human Services, National Institutes of Health. Bethesda, MD.
2. The DCCT Research Group. 1993. The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329 : 978 986.
3. The UKPDS Study Group. 1998. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 : 837 853.
4. Palmer, J.P., G.A. Fleming, C.J. Greenbaum, et al. 2004. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 53 : 250 264.
5. TrialNet Investigators. Improving Metabolic Assessments in Type 1 Diabetes Mellitus Clinical Trials. http://clinicaltrials.gov/show/NCT00105352.
6. Bonner-Weir, S.B. & A. Sharma. 2006. Are there pancreatic progenitor cells from which new islets form after birth? Nat. Clin. Pract. Endocrinol. Metab. 2 : 240 241.
7. Dor, Y. 2006. β-cell proliferation is the major source of new pancreatic cells. Nat. Clin. Pract. Endocrinol. Metab. 2 : 242 243.
8. Suarez-Pinzon, W.L., Y. Yan, R. Power, et al. 2005. Combination therapy with epidermal growth factor and gastrin increases β-cell mass and reverses hyperglycemia in diabetic NOD mice. Diabetes 54 : 2596 2601.
9. Fleming, A. & L. Rosenberg. 2007. Prospects and challenges for islet regeneration as a treatment for diabetes: A review of islet neogenesis associated protein. J. Diab. Sci. Technol. 1 : 231 244.
10. Yang, Z., M. Chen, J.D. Carter, et al. 2006. Combined treatment with lisofylline and exendin-4 reverses autoimmune diabetes. Biochem. Biophys. Res. Commun. 344 : 1017 1022.
11. Rosenberg, L., M. Lipsett, J.W. Yoon, et al. 2004. A pentadecapeptide fragment of islet neogenesis-associated protein increases beta-cell mass and reverses diabetes in C57BL/6J mice. Ann. Surg. 240 : 875 884.
12. Nadler, J.L. Manuscript in preparation. Quoted by permission.
13. Guidance for Industry. Nonclinical Safety Evaluation of Drug Biologic Combinations. U.S. Department of Health and Human Services, Food and Drug Administration, CDER. March 2006. http://www.fda.gov
14. Food and Drug Administration 21 CFR 300.50.
15. Morrison, T. Combo drugs prepare to tap underserved obesity market. Online at http://www.bioworld.com/.
16. http://www.insmed.com.
17. DiMasi, J., R. Hansen & H. Grabowski 2003). The price of innovation: New estimates of drug development costs. J. Health Econ. 22 (2 151 185.
18. News in Brief. 2007. Selected research collaborations. Nat. Biotechnol. 25 : 1339 1340.